Navigation Links
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
Date:11/11/2013

LONDON, Nov. 11, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme (GBM).

Glioma describes any tumor that arises from the glial tissue of the brain. GBM is a particularly aggressive tumor that forms from abnormal growth of glial tissue. According to the New England Journal of Medicine, GBM accounts for approximately 50% of the 22,500 new cases of brain cancer diagnosed in the United States each year. Treatment options are limited and expected survival is a little over one year. GBM is considered a rare, or orphan, disease by the FDA and the European Medicines Agency, or EMA.

This study follows several years of pre-clinical research conducted by GW in the field of glioma which has demonstrated that cannabinoids inhibit the viability of glioma cells both in vitro and in vivoi,ii via apoptosis or programmed cell death, may also affect angiogenesis, and have demonstrated tumor growth-inhibiting action and an improvement in the therapeutic efficacy of temozolomide, a standard treatment for glioma. In addition, GW has shown tumor response to be positively associated with tissue levels of cannabinoids. GW has identified the putative mechanism of action for our cannabinoid product candidate, where autophagy and programmed cell death are stimulated via stimulation of the TRB3 pathway.

"We are very excited about moving this compound into further human study and the prospects of cannabinoids as new anti-cancer treatments. This is GW's first clinical study of cannabinoids as a potential treatment to inhibit tumor growth," stated Dr. Stephen Wri
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 25, 2014 The report ... & by Geography - Global Trends & Forecast ... with respect to market drivers, opportunities, and trends ... tables and 27 figures spread through 217 slides ... Global Trends & Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html ...
(Date:10/25/2014)... October 23, 2014 ViaDerma, ... pharmaceutical company devoted to bringing new products to ... 2015. , ViaDerma has developed an innovative, patent-pending ... rapid mass transfer of pharmaceutical active ingredients to ... provide immediate localized therapy. The transdermal delivery method ...
(Date:10/25/2014)... 2014 BioProcess International (BPI), a ... 2014 BioProcess International Awards. The awards celebrate the ... and technology applications that will allow the industry ... global patient base. , Winners and finalists were ... very entertaining and exciting awards dinner and ceremony ...
(Date:10/25/2014)... According to new market research report "Data ... Enterprise, Telecom), by Design Types (Electrical, Mechanical), and ... 3, Tier 4) - Global Forecast to 2019", ... Center Construction Market into various segments with an ... report also identifies the factors driving this market, ...
Breaking Biology Technology:Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 2BioProcess International Announces Winners of the 2014 BioProcess International Awards 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 5Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4
... 15, 2011 Dr. Huda Y. Zoghbi ,  director ... (NRI) at Texas Children,s Hospital and ... 2011 Neuroscience Prize of The Peter and Patricia Gruber Foundation ... mysteries behind a number of devastating neurological disorders, including Rett ...
... June 15, 2011 Palatin Technologies, Inc. (NYSE Amex: ... for sexual dysfunction indications, announced presentation and publication of ... male sexual arousal.  The underlying study was supported by ... of the New York Presbyterian Hospital and the Weill ...
... Pharma IQ is pioneering new HTA discussion platform with launch,of ... and CER Forum , which will take an innovative form ... Health Technology Assessment has recently observed an,unprecedented global  expansion. Clinical ... UK, while clinical benefit is the main focus in France ...
Cached Biology Technology:Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 2Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 3Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 4Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 5Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 6Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal 2Health Technology Assessment Goes Online 2Health Technology Assessment Goes Online 3
(Date:10/25/2014)... , Oct.  22, 2014   MedNet Solutions ... clinical study management systems, is pleased to announce the ... two-day event – to be held in ... on track to have record attendance and promises to ... The focus of the meeting is ...
(Date:10/25/2014)... 2014 This report covers the specifics of ... in heavy pursuit of research due to its versatility ... to other RNA components. miRNA,s non-coding nature and ability ... for use as a biomarker for a variety of ... diagnostics for the advancement in therapeutic development. Furthermore there ...
(Date:10/25/2014)... 2014 A recent report, "Genetic Testing Market ... and future genetic testing market. A comprehensive introduction of ... in this report. On account of our analysis of ... strengths and challenges; forecast for genetic testing has been ... grow at a CAGR of around 9% during 2013-2018. ...
Breaking Biology News(10 mins):MedNet Solutions To Host Third Annual iMedNet User Group Meeting 2MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Genetic Testing Market Outlook 2018 2
... Boulder, Colo., USA - Two new Geology ... the Cascade arc" and "Silica gel formation during fault ... cover everything from the discovery of fossilized whale "intestinal ... of the 2010 Eyjafjallajkull volcano eruption to new findings ...
... most basic processes -- transcription of the genetic code ... a police force that controls the flow of vehicles. ... in Nature Communications , might facilitate the development ... of disorders. Transcription indeed involves a step resembling ...
... This news release is available in German . ... diarrhoea -- these symptoms could point to an infection with ... based on a syringe-like injection apparatus called injectisome. For the ... the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany, ...
Cached Biology News:Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 2Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 3Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 4Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 5Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 6Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 7Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 8Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 9Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 10Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 11Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 12Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 13Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 14Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 15Gene decoding obeys road traffic rules 23-D molecular syringes 23-D molecular syringes 3
Gelatin 100 mm Culture Dishes...
BD Primaria 100 mm Cell Culture Dish, surface-modified polystyrene for enhanced cell culture. (200/ca) Packaging: 20 / sleeve, 200 / case ...
...
Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
Biology Products: